RESEARCH ON SALIVARY GLANDS AND SECRETIONS NIH GUIDE, Volume 22, Number 1, January 8, 1993 PA NUMBER: PA-93-035 P.T. 34 Keywords: Oral Diseases Clinical Medicine, General National Institute of Dental Research PURPOSE The National Institute of Dental Research (NIDR) supports studies to improve knowledge of the development, structure, function, and diseases of the salivary glands and to determine the influence of salivary constituents on oral health. Toward this end, the NIDR seeks to enhance its support of basic and clinical research in the broad area of the salivary system. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement (PA), Research on Salivary Glands and Secretions, is related to the priority area of oral health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Domestic applications may include international components. Foreign institutions are not eligible for the First Independent Research Support and Transition (FIRST) (R29) award. Applications from minority individuals and women are encouraged. Special eligibility requirements specified in the pertinent guidelines for the various mechanisms available for support of this program must be met. MECHANISMS OF SUPPORT The mechanisms available for support of this program include the traditional research project grant (R01), the program project grant (P01), the First Independent Research Support and Transition (FIRST) (R29) award, and the small grant (R03). Because the nature and scope of the research proposed in response to this PA may vary, it is anticipated that the size of an award will vary also. RESEARCH OBJECTIVES Background Salivary gland research over the past two decades has been compartmentalized into two general areas: (1) salivary secretions (extracellular events) and (2) salivary glands (intracellular processes). Our knowledge of salivary secretions has proceeded at a faster pace than that of intracellular processes. Nevertheless, salivary research is at a crossroads due to the emergence of new biologies, most notably recombinant technologies, cell biology, and protein engineering. Indeed, the future of salivary research will require the integration of these new disciplines with the more traditional disciplines. Salivary researchers are at the critical threshold of having a large volume of scientific information that can be applied clinically towards enhancing natural defense mechanisms. For example, studies in the not-too-distant future could be directed toward topical vaccines against oral disease, the development of artificial salivas, or the diagnostic use of sialochemistry by dental practitioners. Before these clinical goals can be achieved, however, additional research is needed regarding the intracellular and extracellular events that modulate saliva secretion and function. Finally, clinical applications will demand consideration of normal vs. the compromised host, normal vs. high-risk populations, and local vs. systemic diseases in order to develop the appropriate diagnostic and treatment modalities. Research Goals and Scope The NIDR has been a mainstay of support for research and related training on salivary glands and their secretions and has thus contributed to advances in basic research and furthered progress in understanding diseases or syndromes in which salivary gland function is compromised. Based on recommendations by the Dental Research Programs Advisory Committee at its June 7-8, 1988 meeting, the NIDR "Broadening the Scope: Long-Range Research Plan for the Nineties," and the NIDR-sponsored international conference on "Contemporary Developments in Salivary Research" organized by Dr. Michael J. Levine and held on November 6-10, 1991 at Buffalo, New York, the NIDR desires to enhance its support of both basic and clinical research in the broad area of this announcement. Accordingly, applications are invited for research project grants (including minority research supplements), program project grants, FIRST awards, and small grants related, but not limited to, the following areas: o Description of the characteristics of the salivary-associated lymphoid tissue with emphasis on: (a) the mechanisms of homing of immune component cells to and within salivary glands, (b) the cellular elements and factors regulating differentiation and antibody production within specific gland types, including neuropeptide modulation of salivary immunity, (c) the intrinsic and extrinsic factors involved in the ontogeny of salivary immunity, and (d) specific enhancement of host defenses using local antigen delivery methods. o Definition of the molecular mechanisms involved in salivary secretion with emphasis on: (a) the diversity of signal transduction processes present in different salivary tissues and species, (b) the mechanisms of sorting and packaging of stored proteins into secretory granules in acinar cells, and (c) the mechanisms of secretory granule-plasma membrane fusion and its role on the process of exocytosis. o Further definition of the mechanisms of salivary-specific gene expression in developing and adult glands of various species with emphasis on: (a) the trans-acting factors that modulate gene transcription, and (b) the exogenous factors that modulate gene expression, thereby enabling genetic manipulation of salivary glands to address clinical problems. o Development of sophisticated model systems (transgenic animals and immortalized salivary gland epithelial cell lines with appropriate phenotypic expression) to investigate normal cellular processes and those evident in disease. o Extension of studies of the structure and function of salivary macromolecules to determine specific functional domains. o Confirmation of the biological role of individual salivary molecules in vivo. o Definition of salivary function in acquired immune deficiency syndrome (AIDS) and clarification of the role of salivary secretions in preventing oral transmission of human immunodeficiency virus (HIV). o Further research on the use of saliva to diagnose and monitor drug therapy and abuse, endocrine function, systemic disease, oral health, genetic defects, nutritional status, and age-specific changes. o Further investigations on the epidemiology, etiology, pathogenesis, diagnosis, and treatment of salivary gland disorders, such as Sjogren's syndrome. o Development of new sialogogues and improved, long-acting saliva substitutes. o Development of methods to expand and improve function of residual salivary gland tissue after destructive disease or therapy (e.g., radiation or chemotherapy to treat head and neck cancers). This research should include methods aimed at tissue repair and regeneration. o Development of organoids and techniques for the preservation and transplantation of salivary glands. It should be reemphasized that the above list of potential areas of investigation is not intended to be either comprehensive or exclusive, nor is it in order of priority. Rather, it is intended to exemplify the wide variety of new and/or continuing program emphases. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk for the disease, disorder or condition under study; special emphasis must be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale must be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans [including American Indians or Alaskan Natives], Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the review will be deferred until the information is provided. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications will be accepted in accordance with the receipt, Initial Review Group, National Advisory Council, and earliest possible beginning dates specified in the pertinent application kits. The specific application forms and kits required in this connection are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7441. The YES box must be checked and the title, Research on Salivary Glands and Secretions, and number of the announcement must be typed in Section 2a on the face page of the application form PHS 398 (rev. 9/91). FIRST award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW PROCEDURES Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit in accordance with standard NIH peer review procedures and the review criteria customary for the support mechanism selected. Following scientific-technical review, the applications will receive a second-level review by one or more appropriate national advisory councils or boards. AWARD CRITERIA Applications recommended for further consideration will compete for available funds with all other applications. The following will be considered in making funding decisions: quality of the proposed project as determined by peer review, availability of funds, and program balance among research areas of the announcement. The NIDR appreciates the value of complementary funding from other public and private sources, including foundations and industrial concerns, for activities that will complement and expand those supported by the NIDR. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: G.G. Roussos, Ph.D. Director, Salivary Research and Oral Biology Centers Program Extramural Program National Institute of Dental Research Westwood Building, Room 509 Bethesda, MD 20892 Telephone: (301) 496-7784 Direct inquiries regarding fiscal matters to: Ms. Theresa Ringler Chief, Grants Management Section Extramural Program National Institute of Dental Research Westwood Building, Room 510 Bethesda, MD 20892 Telephone: (301) 496-7437 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.121. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||